Vascular targeting by EndoTAG™‐1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer | Zendy

Eichhorn Martin E. | Zendy; Ischenko Ivan | Zendy; Luedemann Siiri | Zendy; Strieth Sebastian | Zendy; Papyan Armine | Zendy; Werner Alexander | Zendy; Bohnenkamp Hermann | Zendy; Guenzi Eric | Zendy; Preissler Gerhard | Zendy; Michaelis Uwe | Zendy; Jauch KarlWalter | Zendy; Bruns Christiane J. | Zendy; Dellian Marc | Zendy

Premium

Vascular targeting by EndoTAG™‐1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer

Author(s) -

Eichhorn Martin E.,

Ischenko Ivan,

Luedemann Siiri,

Strieth Sebastian,

Papyan Armine,

Werner Alexander,

Bohnenkamp Hermann,

Guenzi Eric,

Preissler Gerhard,

Michaelis Uwe,

Jauch KarlWalter,

Bruns Christiane J.,

Dellian Marc

Publication year - 2009

Publication title -

international journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.475

H-Index - 234

eISSN - 1097-0215

pISSN - 0020-7136

DOI - 10.1002/ijc.24846

Subject(s) - gemcitabine , pancreatic cancer , medicine , chemotherapy , paclitaxel , combination therapy , lung cancer , metastasis , cancer , distribution (mathematics) , pharmacology , oncology , cancer research , mathematical analysis , mathematics

Cationic lipid complexed paclitaxel (EndoTAG™‐1) is a novel vascular targeting agent for the treatment of cancer. Here, the aim was to investigate intratumoral drug distribution after EndoTAG™‐1 therapy and analyze the impact of EndoTAG™‐1 scheduling on antitumoral efficacy. The therapeutic effect of EndoTAG™‐1 in combination with conventional gemcitabine or cisplatin therapy was evaluated in L3.6pl orthotopic pancreatic cancer and a subcutaneous Lewis lung (LLC‐1) carcinoma model. Oregon Green paclitaxel encapsulated in cationic liposomes in combination with intravital fluorescence microscopy clearly exhibited delivery of the drug by EndoTAG™‐1 to the tumor endothelium, whereas Oregon Green paclitaxel dissolved in cremophor displayed an interstitial distribution pattern. The therapeutic efficacy of EndoTAG™‐1 was critically dependent on the application schedule with best therapeutic results using a metronomic rather than a maximum tolerated dose application sequence. The combination of EndoTAG™‐1 therapy and cytotoxic chemotherapy significantly enhanced antitumoral efficacy in both tumor models. Interestingly, only EndoTAG™‐1 in combination with gemcitabine was able to inhibit the incidence of metastasis in pancreatic cancer. In conclusion, vascular targeting tumor therapy by EndoTAG™‐1 combined with standard small molecular chemotherapy results in markedly enhanced antitumoral efficacy. Therefore, this combination represents a promising novel strategy for clinical cancer therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research